SG Americas Securities’s Dianthus Therapeutics DNTH Stock Holding History

SG Americas Securities’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$891K	Buy	9,143 +2,136	+30%	+$187K	﹤0.01%	1959
2026 Q1	$588K	Sell	7,007 -11,558	-62%	-$669K	﹤0.01%	2091
2025 Q4	$765K	Buy	+18,565	New	+$720K	﹤0.01%	2226
2025 Q2	–	Sell	-7,101	Closed	-$129K	–	3098
2025 Q1	$129K	Sell	7,101 -2,552	-26%	-$56.2K	﹤0.01%	2856
2024 Q4	$210K	Buy	9,653 +814	+9%	+$20.9K	﹤0.01%	2109
2024 Q3	$242K	Buy	8,839 +4,506	+104%	+$126K	﹤0.01%	2340
2024 Q2	$112K	Buy	+4,333	New	+$104K	﹤0.01%	2482
2021 Q4	–	Sell	-915	Closed	-$107K	–	3482
2021 Q3	$107K	Buy	+915	New	+$107K	﹤0.01%	3636
2020 Q3	–	Sell	-631	Closed	-$76K	–	2878
2020 Q2	$76K	Buy	+631	New	+$88.9K	﹤0.01%	3452

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

SG Americas Securities's DNTH Position: Q2 2026 in Review

SG Americas Securities increased its Dianthus Therapeutics (DNTH) stake by 30% in Q2 2026, buying an estimated $187K and bringing the position to 9,143 shares worth $891K. The position accounts for ﹤0.01% of the portfolio, ranked #1959.

SG Americas Securities first reported a position in DNTH in Q2 2020 and has held it in 9 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

SG Americas Securities held 9,143 shares of Dianthus Therapeutics worth $891K as of Q2 2026.
SG Americas Securities bought 2,136 Dianthus Therapeutics shares in Q2 2026, an estimated $187K.
Dianthus Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1959 holding.
SG Americas Securities first reported a position in Dianthus Therapeutics in Q2 2020 and has held it in 9 quarters since.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.